ChemicalBook > CAS DataBase List > (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide

(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide

(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Structure
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide
  • CAS No.1492952-76-7
  • Chemical Name:(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide
  • CBNumber:CB23133462
  • Molecular Formula:C20H18ClF2N5O3
  • Formula Weight:449.84
  • MOL File:1492952-76-7.mol
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Property
  • Boiling point 631.7±55.0 °C(Predicted)
  • Density 1.518±0.06 g/cm3(Predicted)
  • storage temp. Store at -20°C
  • solubility DMSO:93.0(Max Conc. mg/mL);206.74(Max Conc. mM)
    Ethanol:90.0(Max Conc. mg/mL);200.07(Max Conc. mM)
  • form A crystalline solid
  • pka 10.81±0.70(Predicted)
  • color White to off-white
  • FDA UNII L1F3R18W77
  • NCI Drug Dictionary asciminib
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H315-H319-H335
  • Precautionary statements P261-P305+P351+P338

(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Chemical Properties,Usage,Production

  • Description Asciminib is the first-in-class Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) inhibitor, which was granted accelerated approval in 2021 for patients with Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia (CML) in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs), and for adult patients with Ph+ CML in chronic phase with the T315I mutation. Asciminib binds to a myristoyl site of the BCR-ABL1 protein and locks the protein into an inactive conformation through a mechanism distinct from those of all other orthosteric TKIs such as imatinib, thus overcoming drug resistance arising from ATPbinding site mutations. Asciminib mimics the function of the myristoylated N-terminus of ABL1 and restores the natural autoinhibition of the ABL1b protein.
  • Uses Asciminib comprises ABL kinase inhibitors and/or SLC7A11 inhibitors for the treatment of cancer and central nervous system (CNS) disorders.
  • General Description Class: non-receptor tyrosine kinase
    Treatment: CML
    Elimination half-life = 14.2 h
    Protein binding = 97%
  • in vivo

    Asciminib is undergoing clinical development testing in patients with CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Single doses of 7.5, 15 and 30 mg/kg ABL001, administered to mice bearing KCL- 22 xenografts, inhibits pSTAT5 (Tyr694), which return to baseline at 10, 12 and 16-20h after administration of the dose, respectively. In mice implanted with KCL-22 tumors, the minimum dose of asciminib required for complete regression is 7.5 mg/kg twice a day (BID) or 30 mg/kg once a day (QD), and is tolerated at doses up to 250 mg/kg BID. Similarly, in xenografts derived from patients, treatment with 7.5 and 30 mg/kg asciminib leads to regressions that are maintained during dosing[1].

  • target BCR-ABL1
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Preparation Products And Raw materials
Raw materials
Preparation Products
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Suppliers
Global(133)Suppliers
  • Supplier：
    Biochempartner
  • Tel：0086-13720134139
  • Email：candy@biochempartner.com
  • Country：CHINA
  • ProdList：965
  • Advantage：58
  • Supplier：
    BOC Sciences
  • Tel：+1-631-485-4226
  • Email：inquiry@bocsci.com
  • Country：United States
  • ProdList：19552
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
  • Supplier：
    LEAP CHEM CO., LTD.
  • Tel：+86-852-30606658
  • Email：market18@leapchem.com
  • Country：China
  • ProdList：24727
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：
  • Email：support@targetmol.com
  • Country：United States
  • ProdList：38630
  • Advantage：58
(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide Spectrum
1492952-76-7, (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamideRelated Search:
  • 高纯化学试剂
  • 化学试剂
  • 杂质对照品
  • 抑制剂
  • 医药化学试剂
  • 合成有机化合物配体
  • 原料药
  • 标准品
  • 细胞生物学试剂
  • C20H18ClF2N5O3
  • 阿西米尼—游离态
  • 阿西米尼—游离态/1492952-76-7
  • 化合物ASCIMINIB,10 MM DMSO 溶液
  • 阿思尼布API 游离
  • (R)-N-(4-(氯二氟甲氧基)苯基)-6-(3-羟基吡咯-1-基)-5- (1H-吡唑-5-基)吡啶-3-酰胺
  • ASCIMINIB(阿西米尼)
  • 阿思尼布
  • ABL-001; AB -001; ABL001; ASCIMINIB;
  • ABL-001高含量原粉品质保障
  • ASCIMINIB游离态
  • 阿西米尼
  • N-[4-(氯二氟甲氧基)苯基]-6-[(3R)-3-羟基-1-吡咯烷基]-5-(1H-吡唑-3-基)-3-吡啶甲酰胺
  • 化合物ASCIMINIB
  • (R)-N-(4-(氯二氟甲氧基)苯基)-6-(3-羟基吡咯-1-基)-5- (1H-吡唑-5-基)烟酸酰胺
  • 变构BCR-ABL抑制剂(ASCIMINIB)
  • 1492952-76-7
  • Asimini
  • N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-3-pyridinecarboxamide
  • Asciminib, 10 mM in DMSO
  • (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-3-yl)nicotinamide
  • 2H4,15N]-Asciminib
  • Asciminib
  • ABL-001 (ASCIMINIB)
  • Asciminib (ABL-001)
  • 3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-
  • UNII-L1F3R18W77
  • L1F3R18W77
  • EOS-61420
  • (R)-N- (4-(CHLORODIFLUOROMETHOXY)PHENYL)- 6-(3- HYDROXYPYRROLIDIN-1- YL)-5- (1H-PYRAZOL- 5-YL)NICOTI
  • asciminib free base
  • ABL-001; AB -001; ABL001; ASCIMINIB; ASCIMINIB FREE BASE;
  • ABL001;ABL-001
  • ABL-001
  • (R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide

Home

My